- Email: [email protected]
Association of PD-L1 expression with cancer-specific survival in upper tract urothelial carcinoma
32nd Annual EAU Congress, 24-28 March 2017, London, United Kingdom
1161
Association of PD-L1 expression with cancer-specific survival in upper tract urothelial carcinoma Eur Urol Suppl 2017; 16(3);e2016
Zhang B.1, Yu W.1, Feng X-R.2, Zhao Z.1, Fan Y.1, Meng Y-S.1, Hu S.1, Cui Y.1, He Q.1, Zhang H.3, Li D.3, Zhou L-Q.1, He Z-S.1, Jin J.1, Han W-K.1 1
Peking University First Hospital, Dept. of Urology, Beijing, China, 2Peking University First Hospital, Dept. of Geriatrics, Beijing, China, 3Peking University First Hospital, Dept. of Pathology, Beijing, China INTRODUCTION & OBJECTIVES: Immunotherapy targeting the programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) pathway has shown promising results in several malignancies. The prognostic significance of PD-L1 expression remains unknown in patients with upper tract urothelial carcinoma (UTUC). MATERIAL & METHODS: PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells (TIMCs) and E-cadherin and N-cadherin expression on tumor cells were assessed by immunohistochemistry in a cohort of 162 Chinese patients with UTUC. Associations of PD-L1 expression on tumor cells and TIMCs with clinicopathological characteristics and cancer-specific survival (CSS) were evaluated. RESULTS: Out of 162 patients, 20 (12.3%) and 35 (21.6%) had positive PD-L1 expression on tumor cells and TIMCs, respectively. E-cadherin reduction was associated with PD-L1 positivity on tumor cells (P = 0.048) and PD-L1 negativity on TIMCs (P = 0.033). PD-L1 expression on tumor cells was higher in patients with preoperative chronic kidney disease (CKD) stage 4–5 than those with no CKD or CKD stage 1–3 (P = 0.011). However, gender, tumor stage, lymphovascular invasion and N-cadherin expression were not associated with PD-L1 expression on either tumor cells or TIMCs. Kaplan-Meier analysis showed that PD-L1 expression on tumor cells was associated with shorter CSS (P = 0.007), whereas PD-L1 expression on TIMCs was associated with longer CSS (P = 0.035). Multivariate analyses revealed that PD-L1 expression on tumor cells independently predicted shorter CSS (P = 0.012), whereas PD-L1 expression on TIMCs independently predicted longer CSS (P = 0.034). CONCLUSIONS: PD-L1 was differentially expressed in tumor cells and TIMCs in UTUC. Importantly, PDL1 expression on tumor cells was an independent predictor of shorter CSS, while PD-L1 expression on TIMCs represented an independent predictor of longer CSS.
Eur Urol Suppl 2017; 16(3);e2016 Powered by TCPDF (www.tcpdf.org)
1161
Association of PD-L1 expression with cancer-specific survival in upper tract urothelial carcinoma Eur Urol Suppl 2017; 16(3);e2016
Zhang B.1, Yu W.1, Feng X-R.2, Zhao Z.1, Fan Y.1, Meng Y-S.1, Hu S.1, Cui Y.1, He Q.1, Zhang H.3, Li D.3, Zhou L-Q.1, He Z-S.1, Jin J.1, Han W-K.1 1
Peking University First Hospital, Dept. of Urology, Beijing, China, 2Peking University First Hospital, Dept. of Geriatrics, Beijing, China, 3Peking University First Hospital, Dept. of Pathology, Beijing, China INTRODUCTION & OBJECTIVES: Immunotherapy targeting the programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) pathway has shown promising results in several malignancies. The prognostic significance of PD-L1 expression remains unknown in patients with upper tract urothelial carcinoma (UTUC). MATERIAL & METHODS: PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells (TIMCs) and E-cadherin and N-cadherin expression on tumor cells were assessed by immunohistochemistry in a cohort of 162 Chinese patients with UTUC. Associations of PD-L1 expression on tumor cells and TIMCs with clinicopathological characteristics and cancer-specific survival (CSS) were evaluated. RESULTS: Out of 162 patients, 20 (12.3%) and 35 (21.6%) had positive PD-L1 expression on tumor cells and TIMCs, respectively. E-cadherin reduction was associated with PD-L1 positivity on tumor cells (P = 0.048) and PD-L1 negativity on TIMCs (P = 0.033). PD-L1 expression on tumor cells was higher in patients with preoperative chronic kidney disease (CKD) stage 4–5 than those with no CKD or CKD stage 1–3 (P = 0.011). However, gender, tumor stage, lymphovascular invasion and N-cadherin expression were not associated with PD-L1 expression on either tumor cells or TIMCs. Kaplan-Meier analysis showed that PD-L1 expression on tumor cells was associated with shorter CSS (P = 0.007), whereas PD-L1 expression on TIMCs was associated with longer CSS (P = 0.035). Multivariate analyses revealed that PD-L1 expression on tumor cells independently predicted shorter CSS (P = 0.012), whereas PD-L1 expression on TIMCs independently predicted longer CSS (P = 0.034). CONCLUSIONS: PD-L1 was differentially expressed in tumor cells and TIMCs in UTUC. Importantly, PDL1 expression on tumor cells was an independent predictor of shorter CSS, while PD-L1 expression on TIMCs represented an independent predictor of longer CSS.
Eur Urol Suppl 2017; 16(3);e2016 Powered by TCPDF (www.tcpdf.org)